Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.03, $0.32 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $177.35 million versus the consensus estimate of $172.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.